JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

25.37 0.32

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

25.3

Максимум

26.46

Ключови измерители

By Trading Economics

Приходи

7.7M

-41M

Продажби

3.5M

110M

Марж на печалбата

-37.032

Служители

1,869

EBITDA

1.4M

-55M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+119.71% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1.2B

3B

Предишно отваряне

25.05

Предишно затваряне

25.37

Настроения в новините

By Acuity

100%

0%

359 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.10.2025 г., 23:32 ч. UTC

Горещи акции

Stocks to Watch: Amazon, Reddit, SPS Commerce

30.10.2025 г., 23:02 ч. UTC

Печалби

AIA Group 3Q Value of New Business Grew

30.10.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30.10.2025 г., 23:00 ч. UTC

Печалби

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30.10.2025 г., 22:59 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

30.10.2025 г., 22:59 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30.10.2025 г., 22:56 ч. UTC

Пазарно говорене

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30.10.2025 г., 22:35 ч. UTC

Печалби

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30.10.2025 г., 22:35 ч. UTC

Печалби

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30.10.2025 г., 22:31 ч. UTC

Печалби

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30.10.2025 г., 22:29 ч. UTC

Печалби

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30.10.2025 г., 22:27 ч. UTC

Печалби

Minas Buenaventura 3Q EPS 66c >BVN

30.10.2025 г., 22:27 ч. UTC

Печалби

Minas Buenaventura 3Q Rev $431M >BVN

30.10.2025 г., 22:27 ч. UTC

Печалби

Minas Buenaventura 3Q Net $179M >BVN

30.10.2025 г., 22:16 ч. UTC

Пазарно говорене
Печалби

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30.10.2025 г., 22:14 ч. UTC

Печалби

Review & Preview: A Tech Earnings Storm -- Barrons.com

30.10.2025 г., 22:00 ч. UTC

Печалби
Придобивния, сливания и поглъщания

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30.10.2025 г., 21:39 ч. UTC

Печалби

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30.10.2025 г., 21:26 ч. UTC

Печалби

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30.10.2025 г., 21:14 ч. UTC

Пазарно говорене
Печалби

Apple Sees Record Quarterly Services Revenue -- Market Talk

30.10.2025 г., 21:09 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

30.10.2025 г., 21:09 ч. UTC

Пазарно говорене
Печалби

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30.10.2025 г., 21:04 ч. UTC

Печалби

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30.10.2025 г., 21:03 ч. UTC

Печалби

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30.10.2025 г., 21:03 ч. UTC

Печалби

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30.10.2025 г., 21:00 ч. UTC

Печалби

Eldorado Gold Skouries on Track for 1Q of 2026

30.10.2025 г., 21:00 ч. UTC

Печалби

Eldorado Gold 3Q Adj EPS 41c >EGO

30.10.2025 г., 21:00 ч. UTC

Печалби

Eldorado Gold 3Q Rev $434.7M >EGO

30.10.2025 г., 21:00 ч. UTC

Печалби

Eldorado Gold 3Q Net $56M >EGO

30.10.2025 г., 21:00 ч. UTC

Печалби

Eldorado Gold 3Q EPS 27c >EGO

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

119.71% нагоре

12-месечна прогноза

Среден 55.63 USD  119.71%

Висок 74 USD

Нисък 39 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

6

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat